guest ::
| Home > Publications database > The coding microsatellite mutation profile of PMS2-deficient colorectal cancer. > print |
| Home > Publications database > The coding microsatellite mutation profile of PMS2-deficient colorectal cancer. > print |
| 001 | 169971 | ||
| 005 | 20240229133701.0 | ||
| 024 | 7 | _ | |a 10.1016/j.yexmp.2021.104668 |2 doi |
| 024 | 7 | _ | |a pmid:34302852 |2 pmid |
| 024 | 7 | _ | |a 0014-4800 |2 ISSN |
| 024 | 7 | _ | |a 1096-0945 |2 ISSN |
| 024 | 7 | _ | |a altmetric:110167008 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2021-01671 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Bajwa-Ten Broeke, Sanne W |b 0 |
| 245 | _ | _ | |a The coding microsatellite mutation profile of PMS2-deficient colorectal cancer. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2021 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1642169944_15951 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #LA:F210# / 2021 Oct;122:104668 |
| 520 | _ | _ | |a Lynch syndrome (LS) is caused by a pathogenic heterozygous germline variant in one of the DNA mismatch repair (MMR) genes: MLH1, MSH2, MSH6 or PMS2. LS-associated colorectal carcinomas (CRCs) are characterized by MMR deficiency and by accumulation of multiple insertions/deletions at coding microsatellites (cMS). MMR deficiency-induced variants at defined cMS loci have a driver function and promote tumorigenesis. Notably, PMS2 variant carriers face only a slightly increased risk of developing CRC. Here, we investigate whether this lower penetrance is also reflected by differences in molecular features and cMS variant patterns. Tumor DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissue cores or sections (n = 90). Tumors originated from genetically proven germline pathogenic MMR variant carriers (including 14 PMS2-deficient tumors). The mutational spectrum was analyzed using fluorescently labeled primers specific for 18 cMS previously described as mutational targets in MMR-deficient tumors. Immune cell infiltration was analyzed by immunohistochemical detection of T-cells on FFPE tissue sections. The cMS spectrum of PMS2-deficient CRCs did not show any significant differences from MLH1/MSH2-deficient CRCs. PMS2-deficient tumors, however, displayed lower CD3-positive T-cell infiltration compared to other MMR-deficient cancers (28.00 vs. 55.00 per 0.1 mm2, p = 0.0025). Our study demonstrates that the spectrum of potentially immunogenic cMS variants in CRCs from PMS2 gene variant carriers is similar to that observed in CRCs from other MMR gene variant carriers. Lower immune cell infiltration observed in PMS2-deficient CRCs could be the result of alternative mechanisms of immune evasion or immune cell exclusion, similar to those seen in MMR-proficient tumors. |
| 536 | _ | _ | |a 316 - Infektionen, Entzündung und Krebs (POF4-316) |0 G:(DE-HGF)POF4-316 |c POF4-316 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 650 | _ | 7 | |a HNPCC |2 Other |
| 650 | _ | 7 | |a Hereditary colorectal cancer |2 Other |
| 650 | _ | 7 | |a Immunology of cancer |2 Other |
| 650 | _ | 7 | |a Molecular pathways |2 Other |
| 700 | 1 | _ | |a Ballhausen, Alexej |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Ahadova, Aysel |0 P:(DE-He78)07eef6d38a91f4642c810745c5bf5000 |b 2 |u dkfz |
| 700 | 1 | _ | |a Suerink, Manon |b 3 |
| 700 | 1 | _ | |a Bohaumilitzky, Lena |0 P:(DE-He78)a7f54298fcba548e34453b02202e6519 |b 4 |u dkfz |
| 700 | 1 | _ | |a Seidler, Florian |0 P:(DE-He78)42ccf6cd47fe67a45f6c7ba82ef71cb4 |b 5 |u dkfz |
| 700 | 1 | _ | |a Morreau, Hans |b 6 |
| 700 | 1 | _ | |a van Wezel, Tom |b 7 |
| 700 | 1 | _ | |a Krzykalla, Julia |0 P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9 |b 8 |u dkfz |
| 700 | 1 | _ | |a Benner, Axel |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 9 |u dkfz |
| 700 | 1 | _ | |a de Miranda, Noel F |b 10 |
| 700 | 1 | _ | |a von Knebel Doeberitz, Magnus |0 P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f |b 11 |u dkfz |
| 700 | 1 | _ | |a Nielsen, Maartje |b 12 |
| 700 | 1 | _ | |a Kloor, Matthias |0 P:(DE-He78)028ee60cca729028708496826f077b58 |b 13 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1016/j.yexmp.2021.104668 |g p. 104668 - |0 PERI:(DE-600)1466769-1 |p 104668 |t Experimental and molecular pathology |v 122 |y 2021 |x 0014-4800 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:169971 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)07eef6d38a91f4642c810745c5bf5000 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)a7f54298fcba548e34453b02202e6519 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)42ccf6cd47fe67a45f6c7ba82ef71cb4 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)028ee60cca729028708496826f077b58 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-316 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Infektionen, Entzündung und Krebs |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-01-26 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-01-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-01-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-26 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-26 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EXP MOL PATHOL : 2019 |d 2021-01-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-01-26 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-01-26 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2021-01-26 |
| 920 | 1 | _ | |0 I:(DE-He78)F210-20160331 |k F210 |l Angewandte Tumorbiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F210-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|